Story perspectives

US Drug Prices at Risk as India Faces Tariffs

3/14/2025

36 6

Summary

Goyal Negotiates Drug Prices

As tariffs on Indian pharmaceuticals loom, set to take effect on April 2, the potential for soaring drug prices and shortages in the US grows. With nearly half of generic medications coming from India, Indian Commerce Minister Piyush Goyal is urgently negotiating to protect affordable healthcare for millions, especially the uninsured and low-income patients who rely on these vital medicines.

Summary

India Prepares for Tariffs

As trade tensions rise, India braces for President Trump's impending tariffs on April 2, aimed at tackling a staggering $46 billion trade deficit. This pivotal moment could reshape negotiations for a bilateral trade agreement, with potential repercussions for vital sectors like pharmaceuticals and agriculture that underpin both nations' economies.

History

Historical Context

As U.S.-India trade tensions escalate, the looming tariffs on Indian pharmaceuticals echo historical disputes over drug pricing. In the 1980s, the Hatch-Waxman Act aimed to increase generic drug availability, yet high prices persist. Today, nearly half of U.S. generics come from India, highlighting the ongoing struggle for affordable healthcare amid international trade dynamics. This could significantly impact millions reliant on these medications.

1 of 3

Goyal Negotiates Drug Prices

As tariffs on Indian pharmaceuticals loom, set to take effect on April 2, the potential for soaring drug prices and shortages in the US grows. With nearly half of generic medications coming from India, Indian Commerce Minister Piyush Goyal is urgently negotiating to protect affordable healthcare for millions, especially the uninsured and low-income patients who rely on these vital medicines.

1 / 3